Candel Therapeutics Stock Buy Hold or Sell Recommendation
| CADL Stock | USD 4.84 0.20 3.97% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Candel Therapeutics is 'Sell'. The recommendation algorithm takes into account all of Candel Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Candel Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide. Note, we conduct extensive research on individual companies such as Candel and provide practical buy, sell, or hold advice based on investors' constraints. Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Candel |
Execute Candel Therapeutics Buy or Sell Advice
The Candel recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Candel Therapeutics. Macroaxis does not own or have any residual interests in Candel Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Candel Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Candel Therapeutics Trading Alerts and Improvement Suggestions
| Candel Therapeutics generated a negative expected return over the last 90 days | |
| Candel Therapeutics has high historical volatility and very poor performance | |
| Candel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 31 K. Net Loss for the year was (37.94 M) with loss before overhead, payroll, taxes, and interest of (20.66 M). | |
| Candel Therapeutics currently holds about 86.78 M in cash with (34.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0. | |
| Candel Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Tak Paul Peter of 12900 shares of Candel Therapeutics at 1.55 subject to Rule 16b-3 |
Candel Therapeutics Returns Distribution Density
The distribution of Candel Therapeutics' historical returns is an attempt to chart the uncertainty of Candel Therapeutics' future price movements. The chart of the probability distribution of Candel Therapeutics daily returns describes the distribution of returns around its average expected value. We use Candel Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Candel Therapeutics returns is essential to provide solid investment advice for Candel Therapeutics.
| Mean Return | 0.03 | Value At Risk | -5.78 | Potential Upside | 6.70 | Standard Deviation | 4.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Candel Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Candel Stock Institutional Investors
| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 54.4 K | Bank Of America Corp | 2024-06-30 | 54.4 K | Charles Schwab Investment Management Inc | 2024-09-30 | 46.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 38.9 K | Advisor Group Holdings, Inc. | 2024-06-30 | 25.8 K | Rhumbline Advisers | 2024-06-30 | 23 K | Virtu Financial Llc | 2024-06-30 | 22.6 K | Vontobel Holding Ltd. | 2024-06-30 | 22 K | Jpmorgan Chase & Co | 2024-06-30 | 19.4 K | Northpond Ventures, Llc | 2024-09-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 946.3 K |
Candel Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Candel Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Candel Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Candel stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.21 | |
β | Beta against Dow Jones | 1.90 | |
σ | Overall volatility | 4.66 | |
Ir | Information ratio | -0.02 |
Candel Therapeutics Volatility Alert
Candel Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Candel Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Candel Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Candel Therapeutics Fundamentals Vs Peers
Comparing Candel Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Candel Therapeutics' direct or indirect competition across all of the common fundamentals between Candel Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Candel Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Candel Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Candel Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Candel Therapeutics to competition |
| Fundamentals | Candel Therapeutics | Peer Average |
| Return On Equity | -4.81 | -0.31 |
| Return On Asset | -0.52 | -0.14 |
| Current Valuation | 163.14 M | 16.62 B |
| Shares Outstanding | 32.48 M | 571.82 M |
| Shares Owned By Insiders | 30.39 % | 10.09 % |
| Shares Owned By Institutions | 22.53 % | 39.21 % |
| Number Of Shares Shorted | 1.78 M | 4.71 M |
| Price To Book | 30.41 X | 9.51 X |
| Price To Sales | 436.42 X | 11.42 X |
| Revenue | 31 K | 9.43 B |
| Gross Profit | (20.66 M) | 27.38 B |
| EBITDA | (37.43 M) | 3.9 B |
| Net Income | (37.94 M) | 570.98 M |
| Cash And Equivalents | 86.78 M | 2.7 B |
| Cash Per Share | 3.00 X | 5.01 X |
| Total Debt | 22.76 M | 5.32 B |
| Debt To Equity | 0.38 % | 48.70 % |
| Current Ratio | 14.86 X | 2.16 X |
| Book Value Per Share | 0.44 X | 1.93 K |
| Cash Flow From Operations | (34.24 M) | 971.22 M |
| Short Ratio | 7.72 X | 4.00 X |
| Earnings Per Share | (1.73) X | 3.12 X |
| Target Price | 11.0 | |
| Number Of Employees | 42 | 18.84 K |
| Beta | -0.87 | -0.15 |
| Market Capitalization | 134.29 M | 19.03 B |
| Total Asset | 41.2 M | 29.47 B |
| Retained Earnings | (137.03 M) | 9.33 B |
| Working Capital | 22.61 M | 1.48 B |
| Net Asset | 41.2 M |
Note: Acquisition by Tak Paul Peter of 12900 shares of Candel Therapeutics at 1.55 subject to Rule 16b-3 [view details]
Candel Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Candel . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 77930.03 | |||
| Daily Balance Of Power | (0.42) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 5.07 | |||
| Day Typical Price | 4.99 | |||
| Price Action Indicator | (0.33) | |||
| Period Momentum Indicator | (0.20) | |||
| Relative Strength Index | 28.62 |
About Candel Therapeutics Buy or Sell Advice
When is the right time to buy or sell Candel Therapeutics? Buying financial instruments such as Candel Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Candel Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Thematic Idea Now
Insurance
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Candel Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.